

Q¹
Figure 5 is a sequence comparison of the AAV2 VP1 capsid protein (SEQ ID NO: 25) and the AAV5 VP1 capsid protein (SEQ ID NO: 4).

[Please replace the description of Figure 6 with the following description.]

Figure 6 is a sequence comparison of the AAV2 rep 78 protein (SEQ ID NO: 26) and the AAV5 rep 78 protein (SEQ ID NO: 3).

Please replace the Sequence Listing with the substitute Sequence Listing attached hereto.

REMARKS

The Communication mailed on April 23, 2002 states that there are sequences disclosed in the specification which are not identified by their sequence identifiers (i.e. SEQ ID NO). For example, in Figure 4, nucleotide sequences are disclosed, but not identified by their sequence identifiers in either the figure or the brief description of the drawings on page 7.

Applicants have reviewed the specification and the descriptions of Figures 4, 5 and 6 are amended herein to properly reference the sequences disclosed in these figures. The sequences corresponding to SEQ ID NO:24, SEQ ID NO: 25 and SEQ ID NO: 26 have been included in the attached substitute Sequence Listing. Support for the inclusion of SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26 in the Sequence Listing can be found in Figures 4, 5 and 6 as filed.

Enclosed herewith is a diskette containing a substitute Sequence Listing for this application in computer readable form (CRF) and a paper copy of the substitute Sequence Listing in compliance with 37 C.F.R. § 1.821-1.825. Applicants hereby certify that the information in the computer readable form on the diskette and in the hard copy of the Sequence Listing is the same and includes no new matter. The enclosed computer readable copy and paper copy of the Sequence Listing are believed to bring the Sequence Listing into full compliance with the sequence rules.

Pursuant to the above amendments and remarks, reconsideration and allowance of the pending application is believed to be warranted. The Examiner is invited and encouraged to directly contact the undersigned if such contact may enhance the efficient prosecution of this application to issue.

Payment in the amount of \$110.00 (Extension of time fee) is to be charged to a credit card and such payment is authorized by the signed, enclosed document entitled Credit Card Payment Form PTO-2038. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,



Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
(404) 688-0770

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, BOX SEQUENCE, P. O. Box: 2327, Arlington, VA 22202, on the date shown below.



Gwendolyn D. Spratt

6-24-02

Date

Marked-Up Version of Amendments
Application Serial No. 09/533,427

On page 7, the description of Figure 4

Figure 4 is a sequence comparison of the AAV2 genome (SEQ ID NO: 24) and the AAV5 genome (SEQ ID NO: 1).

On page 7, the description of Figure 5

Figure 5 is a sequence comparison of the AAV2 VP1 capsid protein (SEQ ID NO: 25) and the AAV5 VP1 capsid protein (SEQ ID NO: 4).

On page 7, the description of Figure 6

Figure 6 is a sequence comparison of the AAV2 rep 78 protein (SEQ ID NO: 26) and the AAV5 rep 78 protein (SEQ ID NO: 3).

W140090